Literature DB >> 23010541

Rapamycin-induced modulation of HIV gene transcription attenuates progression of HIVAN.

Partab Rai1, Andrei Plagov, Dileep Kumar, Shresh Pathak, Kamesh R Ayasolla, Amrita K Chawla, Peter W Mathieson, Moin A Saleem, Mohammad Husain, Ashwani Malhotra, Pravin C Singhal.   

Abstract

HIV-associated nephropathy (HIVAN) is the manifestation of HIV gene expression by kidney cells in the presence of specific host factors. Recently, rapamycin (sirolimus) has been demonstrated to modulate the progression of HIVAN. We hypothesized that rapamycin would modulate the progression of HIVAN by attenuating HIV gene expression. To test our hypothesis, three weeks old Tg26 mice (n=6) were administered either vehicle or rapamycin (5 mg/kg, every other day, intraperitoneal) for eight weeks. At the end of the experimental period, the kidneys were harvested. In in vitro studies, human podocytes were transduced with either HIV-1 (NL4-3) or empty vector (EV), followed by treatment with either vehicle or rapamycin. Total RNA and proteins were extracted from renal tissues/cellular lysates and HIV gene transcription/translation was measured by real time PCR and Western blotting studies. Renal histological slides were graded for glomerular sclerosis and tubular dilatation with microcyst formation. Rapamycin attenuated both glomerular and tubular lesions in Tg26 mice. Rapamycin decreased transcription of HIV genes both in renal tissues as well as in HIV-1 transduced podocytes. Our data strongly indicate that HIV-1 long terminal repeat-mediated transcriptional activity was targeted by rapamycin. Rapamycin enhanced podocyte NF-κB and CREB activities but then it decreased AP-1 binding activity. Since expression of HIV genes by kidney cells has been demonstrated to be the key factor in the development HIVAN, it appears that rapamycin-induced altered transcription of HIV genes might have partly contributed to its disease modulating effects.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010541      PMCID: PMC3535680          DOI: 10.1016/j.yexmp.2012.09.009

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  42 in total

1.  Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection.

Authors:  J A Winston; L A Bruggeman; M D Ross; J Jacobson; L Ross; V D D'Agati; P E Klotman; M E Klotman
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

2.  Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999.

Authors:  Richard M Selik; Robert H Byers; Mark S Dworkin
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

3.  Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Authors:  E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

Review 4.  Regulation of mRNA translation in renal physiology and disease.

Authors:  Balakuntalam S Kasinath; Denis Feliers; Kavithalakshmi Sataranatarajan; Goutam Ghosh Choudhury; Myung Ja Lee; Meenalakshmi M Mariappan
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-17

Review 5.  Animal models of HIV-associated nephropathy.

Authors:  Ting-Chi Lu; John Cijiang He; Paul Klotman
Journal:  Curr Opin Nephrol Hypertens       Date:  2006-05       Impact factor: 2.894

Review 6.  Controversies in the pathogenesis of HIV-associated renal diseases.

Authors:  Leslie A Bruggeman; Peter J Nelson
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

7.  The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.

Authors:  Lynda Anne Szczech; Samir K Gupta; Ramez Habash; Antonio Guasch; Robert Kalayjian; Richard Appel; Timothy A Fields; Laura P Svetkey; Katherine H Flanagan; Paul E Klotman; Jonathan A Winston
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

Review 8.  HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management.

Authors:  Mohamed G Atta; Gregory M Lucas; Derek M Fine
Journal:  Expert Rev Anti Infect Ther       Date:  2008-06       Impact factor: 5.091

Review 9.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

Review 10.  The nephropathology in human immunodeficiency virus (HIV-1) infection.

Authors:  J J Bourgoignie; V Pardo
Journal:  Kidney Int Suppl       Date:  1991-12       Impact factor: 10.545

View more
  10 in total

Review 1.  HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment.

Authors:  Avi Z Rosenberg; Saraladevi Naicker; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2015-02-17       Impact factor: 28.314

2.  Tubular cell phenotype in HIV-associated nephropathy: role of phospholipid lysophosphatidic acid.

Authors:  Kamesh R Ayasolla; Partab Rai; Shai Rahimipour; Mohammad Hussain; Ashwani Malhotra; Pravin C Singhal
Journal:  Exp Mol Pathol       Date:  2015-06-14       Impact factor: 3.362

3.  Rapamycin-induced modulation of miRNA expression is associated with amelioration of HIV-associated nephropathy (HIVAN).

Authors:  Kang Cheng; Partab Rai; Andrei Plagov; Xiqian Lan; Peter W Mathieson; Moin A Saleem; Mohammad Husain; Ashwani Malhotra; Pravin C Singhal
Journal:  Exp Cell Res       Date:  2013-04-21       Impact factor: 3.905

4.  Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.

Authors:  Alonso Heredia; Nhut Le; Ronald B Gartenhaus; Edward Sausville; Sandra Medina-Moreno; Juan C Zapata; Charles Davis; Robert C Gallo; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 12.779

5.  Fine-tuning of NFκB by glycogen synthase kinase 3β directs the fate of glomerular podocytes upon injury.

Authors:  Hui Bao; Yan Ge; Ai Peng; Rujun Gong
Journal:  Kidney Int       Date:  2015-01-28       Impact factor: 10.612

6.  HIV-1 enhances mTORC1 activity and repositions lysosomes to the periphery by co-opting Rag GTPases.

Authors:  Alessandro Cinti; Valerie Le Sage; Miroslav P Milev; Fernando Valiente-Echeverría; Christina Crossie; Marie-Joelle Miron; Nelly Panté; Martin Olivier; Andrew J Mouland
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

Review 7.  Interplay between Autophagy, Exosomes and HIV-1 Associated Neurological Disorders: New Insights for Diagnosis and Therapeutic Applications.

Authors:  Chet Raj Ojha; Jessica Lapierre; Myosotys Rodriguez; Seth M Dever; Mohammad Asad Zadeh; Catherine DeMarino; Michelle L Pleet; Fatah Kashanchi; Nazira El-Hage
Journal:  Viruses       Date:  2017-07-06       Impact factor: 5.048

8.  mTOR plays a critical role in p53-induced oxidative kidney cell injury in HIVAN.

Authors:  Partab Rai; Andrei Plagov; Xiqian Lan; Nirupama Chandel; Tejinder Singh; Rivka Lederman; Kamesh R Ayasolla; Peter W Mathieson; Moin A Saleem; Mohammad Husain; Ashwani Malhotra; Praveen N Chander; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-15

Review 9.  Molecular Mechanisms of Injury in HIV-Associated Nephropathy.

Authors:  Samuel J Rednor; Michael J Ross
Journal:  Front Med (Lausanne)       Date:  2018-06-07

Review 10.  Examining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy.

Authors:  Duale Ahmed; David Roy; Edana Cassol
Journal:  Mediators Inflamm       Date:  2018-09-27       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.